Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610891 | 0.87 | GRIN2D (0.40) | GRIN2DGRIN2AGRIN2BGRIN2COPRM1 | |
| SCHEMBL10235792 | 0.86 | CYSLTR2 (0.45) | OPRM1OPRD1OPRK1TAAR1LMNA | |
| SCHEMBL10235814 | 0.86 | CYSLTR2 (0.48) | OPRM1OPRD1OPRK1LPLLIPG | |
| SCHEMBL10235993 | 0.86 | LPL (0.53) | LPLLIPGLTB4R | |
| SCHEMBL10235695 | 0.86 | CYP4F2 (0.44) | LPLLIPGNOS1NOS2LTB4R | |
| SCHEMBL10235791 | 0.86 | CYSLTR2 (0.48) | OPRM1OPRD1OPRK1LPLLIPG | |
| SCHEMBL14642760 | 0.85 | NOS1 (0.40) | LPLLIPGTAAR1NOS1NOS2 | |
| SCHEMBL10235709 | 0.85 | CYP4F2 (0.44) | LPLLIPGTAAR1NOS1NOS2 | |
| SCHEMBL10235712 | 0.84 | CYP4F2 (0.43) | LPLLIPGLTB4R | |
| SCHEMBL10235702 | 0.84 | CYP4F2 (0.43) | LPLLIPGLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140039048-A1 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | ACUCELA INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8076516-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GRIN2D 1365/4885GRIN2A 1771/4885GRIN2B 1137/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GRIN2D 1365/4885GRIN2A 1771/4885GRIN2B 1137/4885 |
| US-20160193181-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GRIN2D 1365/4885GRIN2A 1771/4885GRIN2B 1137/4885 |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | GRIN2D 4213/4885GRIN2A 3586/4885GRIN2B 2864/4885 |
| US-20140039048-A1 | METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES | ALDH1A2, ALDH1A3, RBP4 | GRIN2D 4213/4885GRIN2A 3586/4885GRIN2B 2864/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | GRIN2D 1365/4885GRIN2A 1771/4885GRIN2B 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.